AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11234783
Drug: Patient-delivered partner
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-delivered partner medication (PDPM) for casual partners
Trial: 9678620
Drug: Tamoxifen (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (20 mg/day for 5 years) in adjuvant studies
Trial: 9678620
Drug: Tamoxifen (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (20 mg/day for 5 years) in chemoprevention study
Trial: 8053589
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of rocuronium and mivacurium (1 ED50 rocuronium + 1 ED50 mivacurium, etc.)
Trial: 8053589
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of rocuronium 150 micrograms.kg-1 + Mivacurium 37.5 micrograms.kg-1 (Group 3)
Trial: 2903169
Drug: Idazoxan (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idazoxan (40 mg, orally)
Trial: 2903169
Drug: Idazoxan (iv
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idazoxan (iv administration 20 min before GIT)
Trial: 29490632
Drug: Immune checkpoint
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune checkpoint inhibitors (ICPIs)
Trial: 29440887
Drug: Arformoterol 15
RxNorm normalized name: arformoterol 15 mcg/2 mL inhalation solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arformoterol 15 µg, twice daily
Trial: 23502689
Drug: Online self-help
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Online self-help cognitive behavioral therapy (CBT) package (Overcoming Bulimia Online)
Trial: 19069453
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (CT) with aspirin (125 mg thrice daily)
Trial: 19069453
Drug: Chronotherapy (ChN)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronotherapy (ChN) with aspirin taken once daily at 22.00
Trial: 16809906
Drug: PSE/DAG (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSE/DAG (1.2 g PSE/30 g DAG for 2 weeks)
Trial: 14719295
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment in the treatment group
Trial: 14719295
Drug: Drugs in
RxNorm normalized name: Other antiobesity drugs in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs in the control group
Trial: 9208339
Drug: Incadronate (0.025-1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incadronate (0.025-1.6 mg) in healthy volunteers
Trial: 9208339
Drug: Incadronate (2.5-10.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incadronate (2.5-10.0 mg) in patients with malignancy-associated hypercalcemia
Trial: 7956408
Drug: Simple saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple saline solution nasal irrigation
Trial: 18294083
Drug: extended-release mixed
RxNorm normalized name: Amphetamine Mixed Salts Extended-Release Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: extended-release mixed amphetamine salts (se-AMPH ER, 30 mg)
Trial: 10602721
Drug: Oral cefaclor
RxNorm normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral cefaclor
Trial: 31852538
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of both (Arm 3)
Trial: 27936169
Drug: Synbiotic (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synbiotic (1.5 × 10^10 CFU Ecologic® 825 + 10 g fructo‐oligosaccharides (FOS P6) per day)
Trial: 19225400
Drug: Lopinavir/ritonavir (LPV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir (LPV/r) once daily
Trial: 19225400
Drug: Lopinavir/ritonavir (LPV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir (LPV/r) twice daily
Trial: 19225400
Drug: Lopinavir/ritonavir (LPV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir (LPV/r) once daily and twice daily
Trial: 15562775
Drug: estradiol velerate
RxNorm normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: estradiol velerate (E2V) 1.0 mg/d and medroxyprogestetone acetate (MPA) 2 mg/d
Trial: 8989263
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) therapy at a mean dose of 0.128 +/- 0.003 IU/kg.week for the first month, then 0.23 +/- 0.01 IU/kg.week, divided into daily doses (0.7-4.3 IU/day)
Trial: 7684225
Drug: Iloprost applied
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iloprost applied as an aqueous solution, hydrogels, and fatty ointment at dose levels of at least 50/25 ng/cm2 (intact/stripped skin)
Trial: 7684225
Drug: Iloprost applied
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iloprost applied at high doses (400/150 ng/cm2)
Trial: 7684225
Drug: Iloprost applied
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iloprost applied at a dose of 25 micrograms/100 cm2 once daily for 60 days
Trial: 20497745
Drug: Simvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (40 mg/day) alone for 6 days
Trial: 20497745
Drug: Simvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (40 mg/day) co-administered with linagliptin (10 mg/day) for 6 days
Trial: 19096711
Drug: Generic formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic formulation (Triomune)
Trial: 12628519
Drug: Chlorophyllin (CHL),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorophyllin (CHL), administered three times a day
Trial: 8256356
Drug: Silver sulfadiazine
RxNorm normalized name: Silver Sulfadiazine
DrugBank: Silver sulfadiazine (DB05245)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silver sulfadiazine treatment
Trial: 3512670
Drug: Chlorthalidone 25.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone 25.0 mg
Trial: 3512670
Drug: Chlorthalidone 50.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone 50.0 mg
Trial: 29788364
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 injection plus monthly 50,000 IU maintenance therapy
Trial: 26176640
Drug: Willingness to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Willingness to send biological data to doctors
Trial: 23790699
Drug: Dutch 10-session
RxNorm normalized name: ditch stonecroft extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dutch 10-session community occupational therapy programme
Trial: 18079998
Drug: alpha-Lipoic acid
RxNorm normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha-Lipoic acid (LA) supplementation with hyperbaric oxygen therapy (HBO)
Trial: 18079998
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with hyperbaric oxygen therapy (HBO)
Trial: 16583576
Drug: Savlon douching
RxNorm normalized name: Savlon Dry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Savlon douching (1:1000 solution)
Trial: 16583576
Drug: Povidone-iodine painting
RxNorm normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Povidone-iodine painting (1% solution)
Trial: 11204664
Drug: Hepatic artery
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic artery infusion alternating with systemic therapy (oxaliplatin and fluorouracil (5-FU) with leucovorin)
Trial: 11204664
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of oxaliplatin and fluorouracil (5-FU)
Trial: 9309270
Drug: Morning administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning administration of effervescent calcium carbasalate (ECC equivalent to 160 mg aspirin)
Trial: 9309270
Drug: Evening administration
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evening administration of effervescent calcium carbasalate (ECC equivalent to 160 mg aspirin)
Trial: 9309270
Drug: Effervescent calcium
RxNorm normalized name: Effervescent Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effervescent calcium carbasalate (ECC equivalent to 160 mg aspirin)
Trial: 3736281
Drug: 0.05 mg
RxNorm normalized name: biotin 0.05 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg Ro 17-1812
Trial: 3736281
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg Ro 17-1812
Trial: 3736281
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg Ro 17-1812
Trial: 28231946
Drug: Posaconazole 400
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Posaconazole 400 mg b.i.d.
Trial: 28231946
Drug: Placebo 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 10 mg b.i.d.
Trial: 28231946
Drug: Benznidazole 200
RxNorm normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benznidazole 200 mg + Posaconazole 400 mg b.i.d.
Trial: 28231946
Drug: Benznidazole 200
RxNorm normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benznidazole 200 mg b.i.d.
Trial: 28231946
Drug: Posaconazole 400
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Posaconazole 400 mg b.i.d. (30 days)
Trial: 28231946
Drug: Benznidazole 200
RxNorm normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benznidazole 200 mg b.i.d. (30 days)
Trial: 28231946
Drug: Posaconazole 400
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Posaconazole 400 mg b.i.d. (60 days)
Trial: 28231946
Drug: Benznidazole 200
RxNorm normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benznidazole 200 mg b.i.d. (60 days)
Trial: 28231946
Drug: Benznidazole monotherapy
RxNorm normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benznidazole monotherapy (360 days)
Trial: 24088749
Drug: sitagliptin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sitagliptin + metformin
Trial: 19624691
Drug: Acute metabolic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute metabolic acidosis induced by administration of ammonium chloride (NH4Cl)
Trial: 19624691
Drug: Acute metabolic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute metabolic acidosis induced by administration of ammonium chloride (NH4Cl) in COPD patients
Trial: 15266766
Drug: Standard Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Dose Femarelle (644 mg/day)
Trial: 15266766
Drug: Low Dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Dose Femarelle (344 mg/day)
Trial: 11497198
Drug: Perindopril (P)
DrugBank: Perindopril (DB00790)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perindopril (P) therapy
Trial: 11497198
Drug: Usual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual treatment (UC)
Trial: 3067951
Drug: Human Actrapid
RxNorm normalized name: Human Actrapid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human Actrapid (three times daily pre-prandial doses using a NovoPen) plus Human Ultratard (n = 19)
Trial: 3067951
Drug: Premixed insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Premixed insulin (n = 18)
Trial: 27543905
Drug: Topical tocopherol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tocopherol acetate
Trial: 25534576
Drug: Temozolomide 150
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide 150 mg/m² days 1-7 and 15-21, every 28 days for 8 cycles
Trial: 21546875
Drug: Bethanechol chloride
RxNorm normalized name: Bethanechol Chloride
DrugBank: Bethanechol (DB01019)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bethanechol chloride (Ucholine 20 mg 3 times a day on the third to seventh postoperative day)
Trial: 16434866
Drug: Levofloxacin-azithromycin combined
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin-azithromycin combined triple therapy (omeprazole 20 mg bid, levofloxacin 500 mg od, azithromycin 500 mg od) for 7 days
Trial: 16434866
Drug: Levofloxacin-azithromycin combined
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin-azithromycin combined triple therapy for second-line eradication
Trial: 16434866
Drug: Standard PPI-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard PPI-based triple therapy (omeprazole 20 mg bid, amoxicillin 1.0 g bid, clarithromycin 500 mg bid) for 7 days
Trial: 16434866
Drug: Bismuth-based quadruple
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth-based quadruple therapy (omeprazole 20 mg bid, bismuth 120 mg qid, metronidazole 500 mg tid, tetracycline 500 mg qid) for second-line eradication
Trial: 12606508
Drug: Troglitazone (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone (600 mg/day, n = 4)
Trial: 12606508
Drug: Metformin (approximately
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (approximately 2,000 mg/day, n = 8)
Trial: 16245220
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (600 IU/day) plus Vitamin C (500 mg/day)
Trial: 9588606
Drug: Protonics device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protonics device during activities of daily living (ADL)
Trial: 7518020
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (2 cycles of cis-platinum 100 mg/m2, bleomycin 10 mg/m2 loading dose, followed by 10 mg/m2/day continuous infusion, and vinblastine 3 mg/m2)
Trial: 7518020
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy group
Trial: 2609062
Drug: 50% DMSO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% DMSO gel
Trial: 9295
Drug: Salbutamol (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (4 mg 3 times a day)
Trial: 30646129
Drug: Primaquine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primaquine treatment (high-dose)
Trial: 30646129
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no primaquine treatment)
Trial: 10372711
Drug: L‐T4 substitutive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐T4 substitutive therapy (mean dose, 68 microg daily)
Trial: 10372711
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with subclinical hypothyroidism (before treatment)
Trial: 26963483
Drug: Branched-chain amino
RxNorm normalized name: Branched-chain amino acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branched-chain amino acids (BCAAs) 6 g consumed 10 min before exercise and exercise therapy (twice weekly for 3 months)
Trial: 26963483
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (maltodextrin 6 g consumed 10 min before exercise and exercise therapy)
Trial: 26963483
Drug: BCAAs administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BCAAs administration
Trial: 26963483
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of BCAA intake and exercise therapy
Trial: 18060212
Drug: Paracetamol 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 1500 mg/day
Trial: 16264047
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment including bosentan, sildenafil, and inhaled iloprost
Trial: 7783014
Drug: Implant overdentures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant overdentures with O-ring attachments
Trial: 7783014
Drug: Implant overdentures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant overdentures with magnet attachments
Trial: 2191111
Drug: Systemic metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic metronidazole (three 400 mg tablets daily for 1 week)
Trial: 31422216
Drug: Investigator's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator's choice (IC) of single-agent chemotherapy (methotrexate, docetaxel, or cetuximab)
Trial: 21917518
Drug: Anthracycline-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthracycline-based treatment
Trial: 15496698
Drug: Corticosteroids treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids treatment in head injury (intervention group where consent was waived)
Trial: 15496698
Drug: Corticosteroids treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids treatment in head injury (control group where consent was required)
Trial: 11273944
Drug: 0.05% or
RxNorm normalized name: Sodium Fluoride 0.05% Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% or 0.1% solutions of bupivacaine/fentanyl and ropivacaine/fentanyl
Trial: 11273944
Drug: 0.05% solution
RxNorm normalized name: Equate Nasal Spray 0.05% Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% solution
Trial: 9563925
Drug: Interferon-alpha 2b
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha 2b alone (monotherapy)
Trial: 3592847
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg oxpentifylline thrice daily for 12 weeks
Trial: 3592847
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo tablets for 12 weeks
Trial: 3592847
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg oxpentifylline for MID patients (n = 4)
Trial: 3592847
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg oxpentifylline for PDD patients
Trial: 26564446
Drug: Longitudinal changes
RxNorm normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longitudinal changes in corneal curvature (CC)
Trial: 26564446
Drug: Correlation between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation between axial length (AL) and corneal curvature (CC)
Trial: 22257825
Drug: TMZ plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMZ plus WBI (30 Gy in 10 fractions over 2 weeks with 200 mg TMZ on M/W/F and 300 mg TMZ on T/Th)
Trial: 20680385
Drug: Ice water
RxNorm normalized name: CVS Electrolyte Solution with Zinc (Rice Water)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ice water ingestion (250 ml)
Trial: 8265878
Drug: Buspirone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (20 mg daily for 14 days)
Trial: 3011023
Drug: Guar gum
RxNorm normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guar gum (6.6 g)
Trial: 2890550
Drug: Olsalazine sodium
RxNorm normalized name: Olsalazine Sodium
DrugBank: Olsalazine (DB01250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olsalazine sodium 0.75 g
Trial: 2890550
Drug: Olsalazine sodium
RxNorm normalized name: Olsalazine Sodium
DrugBank: Olsalazine (DB01250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olsalazine sodium 1.5 g
Trial: 2890550
Drug: Olsalazine sodium
RxNorm normalized name: Olsalazine Sodium
DrugBank: Olsalazine (DB01250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olsalazine sodium 3 g
Trial: 30537261
Drug: Troponin T
RxNorm normalized name: Troponin T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troponin T (TnT) elevated to >18 ng/L and NT-proBNP in the highest tertile (9% of all patients)
Trial: 30537261
Drug: Troponin T
RxNorm normalized name: Troponin T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troponin T (TnT) <18 ng/L and NT-proBNP in the lowest tertile (16% of all patients)
Trial: 21455612
Drug: PRT +
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: PRT + fortified milk supplement
Trial: 21455612
Drug: Fortified milk
RxNorm normalized name: Fortified milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortified milk supplement